Tenderwize
Retour à la recherche

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Mar 27, 2027 · 217 days left·Open·Supplies·Framework
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Zolmitriptan (ATC N02CC03).

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with active substance Zolmitriptan (ATC N02CC03)
  • Open-house model: all interested and eligible pharmaceutical companies may participate without selection
Afficher le résumé complet

This is a non-exclusive discount agreement ('open-house model') under § 130a Abs. 8 SGB V for pharmaceuticals containing Zolmitriptan (ATC N02CC03). The AOK Niedersachsen invites all interested pharmaceutical companies to conclude discount agreements without a competitive selection. The agreement period runs from 01 June 2025 to 31 May 2027, with contracts possible at any time during this period. The open-house agreements will be replaced automatically when exclusive discount contracts are awarded (expected 6-8 months after publication of a call for competition). The procedure is not a public contract under EU procurement law; the publication is for transparency purposes. Submission deadlines apply for initial contracts (24 April 2025) and later for monthly join dates. Electronic submission is not allowed; paper submission is required.

Risques

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG or a consortium of such
  • Pharmaceutical products must be authorised for market in Germany under AMG
  • The pharmaceutical entrepreneur must have its registered office within Germany, EU, or EEA (§ 9 Abs. 2 Satz 1 AMG)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Price (discount) criterion; uniform conditions apply to all participants.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

Open-house model for Zolmitriptan (ATC N02CC03) discount agreements. All eligible pharmaceutical companies may join under uniform conditions. Contracts are non-exclusive and will be replaced by exclusive agreements once awarded.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Mar 27, 2027

Détails de la procédure

Date de publication
31 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
207292-2025

Appels d'offres similaires